Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSFailed clinical trials can cost sponsors more than a billion dollars, and waste years of time developing a drug that will never get to market. However, these losses can now be mitigated through the use of artificial intelligence (AI) and machine learning-driven platforms that identify sub-populations of patients within a clinical trial who could respond positively to a treatment.
When sponsors can find these populations and adapt the trial design accordingly, it can reduce the rate of trial failure, rescue a promising molecule for further development, and capture better primary and secondary endpoint data to support approval and payer valuations.
This paper explores how sponsors can leverage AI driven tools, such as IQVIA’s Sub-Population Optimization Solution (SOS), throughout the trial lifecycle to reduce the risk of failure, while improving success rates, and identifying new opportunities in drug development.
The enormous cost of drug development is caused in large part by the high rate of failure. A 2019 study found that less than 14 percent of all drug development programs eventually lead to approval, and that number drops to just six percent for orphan drugs, and a mere 3.4 percent for oncology drugs, which is a dominant category for drug development.
When trials get shut down, sponsors face enormous financial losses — an estimated $800 million to $1.4 billionii — and patients lose the hope of potentially lifesaving treatments coming to market.
While some molecules simply don’t pan out, many trials fail because the trial design did not adequately identify the appropriate population, endpoint, and/or dose selection. This can result in a majority of trial participants not responding as hoped, or adverse events occurring that make safety risks too high. However, with the right data, this high rate of failure doesn’t have to occur.
Within failed trials, there are often sub-populations of patients who respond well to the treatment and suffer no adverse events, but because the overall numbers don’t add up, the trial is abandoned. This means sponsors lose their investment and patients who could potentially benefit from lifesaving treatments are denied these innovations.
These populations can be identified through the use of SOS platforms, which leverage AI and machine learning tools that can rapidly analyze clinical data sets to identify the most promising populations, allowing sponsors to adapt the trial accordingly. When sponsors can identify these sub-populations sooner in the research process, they can adapt the trial to focus on those patients. This increases safety and treatment outcomes through better trial design and can rescue promising trials that would otherwise be deemed failures.
These statistically rigorous analytical platforms feature machine learning algorithms that are programmed to analyze trial data to identify predictive biomarker(s) in treatment populations who are experiencing stronger outcomes. They can be used at various points in the trial lifecycle to identify trends and outliers without bias, to inform trial design, support approval and pricing decisions, and shape market and sales strategies.
The platform utilizes an industry recognized analysis method called Subgroup Identification based on Differential Effect Search (SIDES). SIDES is used to evaluate trial results to help clients answer tough questions about the effectiveness of a drug in development, and to develop effective trial design strategies to maximize their chances of success. These platforms use secure data management technologies and intuitive workflows that automatically query patient data sets based on predetermined features, and deliver results in easy-to-read charts, scatter plots, and summaries.
The easy to read graphical interface allows stakeholders to quickly review and understand which patient populations are responding to the treatment, who among them are facing a higher risk of adverse events, which populations are not likely to benefit, and where there are cut offs. For example, an analysis might show in a series of graphics that patients over the age of 65 with stage three cancer are more likely to respond to the treatment than younger patients, and that those in earlier stages of the cancer have a higher rate of adverse events.
This kind of instant easy to understand data gives investigators and sponsors the insights they need to adapt the trial and select the right patients with greater precision and confidence. That can reduce time, cost and risk across the trial lifecycle, from early discovery through commercialization, and enable sponsors to bring more successful treatments to market.
And when the data shows that no population is having meaningful outcomes, this technology can also save sponsors hundreds of millions of dollars by shutting down failing trials sooner and moving those resources to molecules that have a greater potential of generating returns.
These platforms deliver value at many stages of the trial lifecycle from early stage decision making, through approval, market access and extension studies
Use machine learning-driven analytics to help identify promising patient subgroups, potentially preserving your investment and ensuring valuable therapies reach patients.
Learn how unparalleled data, domain expertise, and technologies enable AI-powered solutions that are purpose-built for healthcare.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Discover unrealized connections and manage your product across the entire lifecycle, from research and development, compliance to launch and commercialization.
Use machine learning-driven analytics to help identify promising patient subgroups, potentially preserving your investment and ensuring valuable therapies reach patients.
Learn how unparalleled data, domain expertise, and technologies enable AI-powered solutions that are purpose-built for healthcare.
